Imperial College London
Portrait Picture

ProfessorJenniferQuint

Faculty of Medicine, School of Public Health

Professor of Respiratory Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 8821j.quint

 
 
//

Location

 

.922Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Bloom:2020:10.1007/s12325-020-01444-5,
author = {Bloom, CI and Cabrera, C and Arnetorp, S and Coulton, K and Nan, C and van, der Valk RJP and Quint, JK},
doi = {10.1007/s12325-020-01444-5},
journal = {Advances in Therapy},
pages = {4190--4208},
title = {Asthma-related health outcomes associated with short-acting beta(2)-agonist inhaler use: an observational UK study as part of the SABINA global program},
url = {http://dx.doi.org/10.1007/s12325-020-01444-5},
volume = {37},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - IntroductionPatients with asthma typically increase short-acting β2-agonists (SABA) use with worsening symptoms. Excessive SABA use may lead to a higher risk of adverse outcomes. We evaluated, in a large population cohort, an association between SABA inhaler use and asthma exacerbations and healthcare utilization.MethodsAs part of the SABINA (SABA use IN Asthma) global program, we conducted a retrospective longitudinal observational study (SABINA I) using UK primary care electronic healthcare records (Clinical Practice Research Datalink; 2007–2017) from asthma patients aged ≥ 12 years. SABA inhaler use was classified as ‘high use ’ 3 canisters/year versus ‘low use’, 0–2 canisters/year. Taking into consideration all their asthma prescriptions, patients were categorized into a treatment step according to 2016 British Thoracic Society (BTS) asthma management guidelines. Multivariable regression assessed the association of SABA inhaler use by BTS treatment steps (grouped as BTS steps 1/2 and 3–5), separately, and with outcomes of exacerbations or asthma-related healthcare utilization (primary care and hospital outpatient consultations); only patients with linked hospital data were included in this analysis.ResultsOf the 574,913 patients included, 218,365 (38%) had high SABA inhaler use. Overall, 336,412 patients had linked hospital data. High SABA inhaler use was significantly associated with an increased risk of exacerbations [adjusted hazard ratio, 95% confidence interval (CI): BTS steps 1/2 = 1.20, 1.16–1.24; BTS steps 3–5 = 1.24, 1.20–1.28], asthma-related primary care consultations [adjusted incidence rate ratio (IRR), 95% CI: BTS steps 1/2 = 1.24, 1.23–1.26; BTS steps 3–5 = 1.13, 1.11–1.15), and asthma-related hospital outpatient consultations (adjusted IRR, 95% CI: BTS steps 1/2 = 1.19, 1.12&ndas
AU  - Bloom,CI
AU  - Cabrera,C
AU  - Arnetorp,S
AU  - Coulton,K
AU  - Nan,C
AU  - van,der Valk RJP
AU  - Quint,JK
DO  - 10.1007/s12325-020-01444-5
EP  - 4208
PY  - 2020///
SN  - 0741-238X
SP  - 4190
TI  - Asthma-related health outcomes associated with short-acting beta(2)-agonist inhaler use: an observational UK study as part of the SABINA global program
T2  - Advances in Therapy
UR  - http://dx.doi.org/10.1007/s12325-020-01444-5
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000552933100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://link.springer.com/article/10.1007%2Fs12325-020-01444-5
UR  - http://hdl.handle.net/10044/1/81432
VL  - 37
ER  -
Download